Literature DB >> 16862115

Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21.

Marc Cruts1, Ilse Gijselinck, Julie van der Zee, Sebastiaan Engelborghs, Hans Wils, Daniel Pirici, Rosa Rademakers, Rik Vandenberghe, Bart Dermaut, Jean-Jacques Martin, Cornelia van Duijn, Karin Peeters, Raf Sciot, Patrick Santens, Tim De Pooter, Maria Mattheijssens, Marleen Van den Broeck, Ivy Cuijt, Krist'l Vennekens, Peter P De Deyn, Samir Kumar-Singh, Christine Van Broeckhoven.   

Abstract

Frontotemporal dementia (FTD) with ubiquitin-immunoreactive neuronal inclusions (both cytoplasmic and nuclear) of unknown nature has been linked to a chromosome 17q21 region (FTDU-17) containing MAPT (microtubule-associated protein tau). FTDU-17 patients have consistently been shown to lack a tau-immunoreactive pathology, a feature characteristic of FTD with parkinsonism linked to mutations in MAPT (FTDP-17). Furthermore, in FTDU-17 patients, mutations in MAPT and genomic rearrangements in the MAPT region have been excluded by both genomic sequencing and fluorescence in situ hybridization on mechanically stretched chromosomes. Here we demonstrate that FTDU-17 is caused by mutations in the gene coding for progranulin (PGRN), a growth factor involved in multiple physiological and pathological processes including tumorigenesis. Besides the production of truncated PGRN proteins due to premature stop codons, we identified a mutation within the splice donor site of intron 0 (IVS0 + 5G > C), indicating loss of the mutant transcript by nuclear degradation. The finding was made within an extensively documented Belgian FTDU-17 founder family. Transcript and protein analyses confirmed the absence of the mutant allele and a reduction in the expression of PGRN. We also identified a mutation (c.3G > A) in the Met1 translation initiation codon, indicating loss of PGRN due to lack of translation of the mutant allele. Our data provide evidence that PGRN haploinsufficiency leads to neurodegeneration because of reduced PGRN-mediated neuronal survival. Furthermore, in a Belgian series of familial FTD patients, PGRN mutations were 3.5 times more frequent than mutations in MAPT, underscoring a principal involvement of PGRN in FTD pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16862115     DOI: 10.1038/nature05017

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  585 in total

1.  Sortilin regulates progranulin action in castration-resistant prostate cancer cells.

Authors:  Ryuta Tanimoto; Alaide Morcavallo; Mario Terracciano; Shi-Qiong Xu; Manuela Stefanello; Simone Buraschi; Kuojung G Lu; Demetrius H Bagley; Leonard G Gomella; Katia Scotlandi; Antonino Belfiore; Renato V Iozzo; Andrea Morrione
Journal:  Endocrinology       Date:  2015-01       Impact factor: 4.736

2.  Core features of frontotemporal dementia recapitulated in progranulin knockout mice.

Authors:  N Ghoshal; J T Dearborn; D F Wozniak; N J Cairns
Journal:  Neurobiol Dis       Date:  2011-09-10       Impact factor: 5.996

3.  Medicine. Progranulin resolves inflammation.

Authors:  Hao Wu; Richard M Siegel
Journal:  Science       Date:  2011-04-22       Impact factor: 47.728

Review 4.  Multifunctional molecule ERp57: From cancer to neurodegenerative diseases.

Authors:  Aubryanna Hettinghouse; Ronghan Liu; Chuan-Ju Liu
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

Review 5.  The genetics of frontotemporal lobar degeneration.

Authors:  Rosa Rademakers; Mike Hutton
Journal:  Curr Neurol Neurosci Rep       Date:  2007-09       Impact factor: 5.081

6.  Proepithelin regulates prostate cancer cell biology by promoting cell growth, migration, and anchorage-independent growth.

Authors:  Giada Monami; Velia Emiliozzi; Alessandro Bitto; Francesca Lovat; Shi-Qiong Xu; Silvia Goldoni; Matteo Fassan; Ginette Serrero; Leonard G Gomella; Raffaele Baffa; Renato V Iozzo; Andrea Morrione
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

7.  Circulating progranulin as a biomarker for neurodegenerative diseases.

Authors:  Roberta Ghidoni; Anna Paterlini; Luisa Benussi
Journal:  Am J Neurodegener Dis       Date:  2012-08-02

8.  C9ORF72 repeat expansions and other FTD gene mutations in a clinical AD patient series from Mayo Clinic.

Authors:  Aleksandra Wojtas; Kristin A Heggeli; Nicole Finch; Matt Baker; Mariely Dejesus-Hernandez; Steven G Younkin; Dennis W Dickson; Neill R Graff-Radford; Rosa Rademakers
Journal:  Am J Neurodegener Dis       Date:  2012-05-16

9.  Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration.

Authors:  Nigel J Cairns; Eileen H Bigio; Ian R A Mackenzie; Manuela Neumann; Virginia M-Y Lee; Kimmo J Hatanpaa; Charles L White; Julie A Schneider; Lea Tenenholz Grinberg; Glenda Halliday; Charles Duyckaerts; James S Lowe; Ida E Holm; Markus Tolnay; Koichi Okamoto; Hideaki Yokoo; Shigeo Murayama; John Woulfe; David G Munoz; Dennis W Dickson; Paul G Ince; John Q Trojanowski; David M A Mann
Journal:  Acta Neuropathol       Date:  2007-06-20       Impact factor: 17.088

10.  Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation.

Authors:  Erik C B Johnson; Eric B Dammer; Duc M Duong; Lingyan Ping; Maotian Zhou; Luming Yin; Lenora A Higginbotham; Andrew Guajardo; Bartholomew White; Juan C Troncoso; Madhav Thambisetty; Thomas J Montine; Edward B Lee; John Q Trojanowski; Thomas G Beach; Eric M Reiman; Vahram Haroutunian; Minghui Wang; Eric Schadt; Bin Zhang; Dennis W Dickson; Nilüfer Ertekin-Taner; Todd E Golde; Vladislav A Petyuk; Philip L De Jager; David A Bennett; Thomas S Wingo; Srikant Rangaraju; Ihab Hajjar; Joshua M Shulman; James J Lah; Allan I Levey; Nicholas T Seyfried
Journal:  Nat Med       Date:  2020-04-13       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.